Skip to main content
Erschienen in: Pediatric Cardiology 7/2013

01.10.2013 | Original Article

Evaluation by N-terminal Prohormone of Brain Natriuretic Peptide Concentrations and Ross Scoring of the Efficacy of Digoxin in the Treatment of Heart Failure Secondary to Congenital Heart Disease With Left-to-Right Shunts

verfasst von: Ozlem Elkiran, Ayse Sandikkaya, Gulendam Kocak, Cemsit Karakurt, Cagatay Taskapan, Saim Yologlu

Erschienen in: Pediatric Cardiology | Ausgabe 7/2013

Einloggen, um Zugang zu erhalten

Abstract

This study aimed to evaluate the effectiveness of digoxin in children with heart failure secondary to left-to-right shunt lesions and normal left ventricular systolic function. The study registered 37 such patients (ages 10 days to 24 months, groups 1 and 2) and used 20 healthy children as a control group (group 3). Left ventricular systolic function, as assessed by conventional echocardiography, was normal in all the subjects. Congestive heart failure was diagnosed by clinical evaluation and modified Ross scoring. Plasma N-terminal prohormone of brain natriuretic peptide (NT-proBNP) concentrations and complete blood counts were assessed in all the children. Group 1 was treated with digoxin, enalapril, and furosemide and group 2 with enalapril and furosemide. Approximately 1 month after starting treatment, the patients were reevaluated by physical and echocardiographic examinations, modified Ross scoring, plasma NT-proBNP concentrations, and complete blood counts. The pre- and posttreatment Ross scores of group 1 (p = 0.377) and group 2 (p = 0.616) did not differ significantly. The NT-proBNP values in both groups decreased after treatment (p = 0.0001). The pre- and posttreatment NT-proBNP values did not differ significantly in group 1 (p = 0.094)) and group 2 (p = 0.372). The pretreatment NT-proBNP values in groups 1 and 2 (p = 0.0001) were significantly higher than in the control group (p = 0.003). A smaller difference was observed between posttreatment NT-proBNP values in group 1 and the control group (p = 0.045). We found no significant difference between the posttreatment NT-proBNP values of group 2 and those of the control group (p = 0.271). The study showed that both treatments currently used to treat heart failure secondary to congenital heart disease with left-to-right shunts and preserved left ventricular systolic function are effective and do not differ significantly. Thus, digoxin does not provide any extra benefit in the treatment of such patients.
Literatur
1.
Zurück zum Zitat Penny DJ, Vick GW III (2010) Novel therapies in childhood heart failure: today and tomorrow. Heart Fail Clin 6:591–621 xCrossRefPubMed Penny DJ, Vick GW III (2010) Novel therapies in childhood heart failure: today and tomorrow. Heart Fail Clin 6:591–621 xCrossRefPubMed
2.
Zurück zum Zitat O’Connor MJ, Rosenthal DN, Shaddy RE (2010) Outpatient management of pediatric heart failure. Heart Fail Clin 6:515–529 ixCrossRefPubMed O’Connor MJ, Rosenthal DN, Shaddy RE (2010) Outpatient management of pediatric heart failure. Heart Fail Clin 6:515–529 ixCrossRefPubMed
3.
Zurück zum Zitat Barnes S, Shields B, Bonney W, Hardin J, Abdulla R (2004) The pediatric cardiology pharmacopoeia: 2004 update. Pediatr Cardiol 25:623–646CrossRefPubMed Barnes S, Shields B, Bonney W, Hardin J, Abdulla R (2004) The pediatric cardiology pharmacopoeia: 2004 update. Pediatr Cardiol 25:623–646CrossRefPubMed
4.
Zurück zum Zitat Kantor PF, Mertens LL (2010) Clinical practice: heart failure in children. Part I: clinical evaluation, diagnostic testing, and initial medical management. Eur J Pediatr 169:269–279CrossRefPubMed Kantor PF, Mertens LL (2010) Clinical practice: heart failure in children. Part I: clinical evaluation, diagnostic testing, and initial medical management. Eur J Pediatr 169:269–279CrossRefPubMed
5.
Zurück zum Zitat Timberlake K, Kantor PF (2011) Pharmacologic therapy of heart failure in children: part of a special series on paediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol Res 64:427–430CrossRefPubMed Timberlake K, Kantor PF (2011) Pharmacologic therapy of heart failure in children: part of a special series on paediatric pharmacology, guest edited by Gianvincenzo Zuccotti, Emilio Clementi, and Massimo Molteni. Pharmacol Res 64:427–430CrossRefPubMed
6.
Zurück zum Zitat Ross RD (2012) The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatr Cardiol 33:1295–1300CrossRefPubMed Ross RD (2012) The Ross classification for heart failure in children after 25 years: a review and an age-stratified revision. Pediatr Cardiol 33:1295–1300CrossRefPubMed
7.
Zurück zum Zitat Johnstone DE, Abdulla A, Arnold JM, Bernstein V, Bourassa M, Brophy J, Davies R, Gardner M, Hoeschen R, Mickleborough L et al (1994) Diagnosis and management of heart failure. Canadian Cardiovascular Society. Can J Cardiol 10(613–631):635–654 Johnstone DE, Abdulla A, Arnold JM, Bernstein V, Bourassa M, Brophy J, Davies R, Gardner M, Hoeschen R, Mickleborough L et al (1994) Diagnosis and management of heart failure. Canadian Cardiovascular Society. Can J Cardiol 10(613–631):635–654
8.
Zurück zum Zitat Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS (2009) NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 30:3–8CrossRefPubMed Nir A, Lindinger A, Rauh M, Bar-Oz B, Laer S, Schwachtgen L, Koch A, Falkenberg J, Mir TS (2009) NT-pro-B-type natriuretic peptide in infants and children: reference values based on combined data from four studies. Pediatr Cardiol 30:3–8CrossRefPubMed
9.
Zurück zum Zitat Koch A, Zink S, Singer H (2006) B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 27:861–866CrossRefPubMed Koch A, Zink S, Singer H (2006) B-type natriuretic peptide in paediatric patients with congenital heart disease. Eur Heart J 27:861–866CrossRefPubMed
10.
Zurück zum Zitat Cantinotti M, Giovannini S, Murzi B, Clerico A (2011) Diagnostic, prognostic, and therapeutic relevance of B-type natriuretic hormone and related peptides in children with congenital heart diseases. Clin Chem Lab Med 49:567–580CrossRefPubMed Cantinotti M, Giovannini S, Murzi B, Clerico A (2011) Diagnostic, prognostic, and therapeutic relevance of B-type natriuretic hormone and related peptides in children with congenital heart diseases. Clin Chem Lab Med 49:567–580CrossRefPubMed
11.
Zurück zum Zitat Gessler P, Knirsch W, Schmitt B, Rousson V, von Eckardstein A (2006) Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery. J Pediatr 148:372–376CrossRefPubMed Gessler P, Knirsch W, Schmitt B, Rousson V, von Eckardstein A (2006) Prognostic value of plasma N-terminal pro-brain natriuretic peptide in children with congenital heart defects and open-heart surgery. J Pediatr 148:372–376CrossRefPubMed
12.
Zurück zum Zitat Price JF, Thomas AK, Grenier M, Eidem BW, O’Brian Smith E, Denfield SW, Towbin JA, Dreyer WJ (2006) B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 114:1063–1069CrossRefPubMed Price JF, Thomas AK, Grenier M, Eidem BW, O’Brian Smith E, Denfield SW, Towbin JA, Dreyer WJ (2006) B-type natriuretic peptide predicts adverse cardiovascular events in pediatric outpatients with chronic left ventricular systolic dysfunction. Circulation 114:1063–1069CrossRefPubMed
13.
Zurück zum Zitat Tan LH, Jefferies JL, Liang JF, Denfield SW, Dreyer WJ, Mott AR, Grenier MA, Dickerson HA, Price JF, Towbin JA, Ou CN, Chang AC (2007) Concentrations of brain natriuretic peptide in the plasma predicts outcomes of treatment of children with decompensated heart failure admitted to the intensive care unit. Cardiol Young 17:397–406CrossRefPubMed Tan LH, Jefferies JL, Liang JF, Denfield SW, Dreyer WJ, Mott AR, Grenier MA, Dickerson HA, Price JF, Towbin JA, Ou CN, Chang AC (2007) Concentrations of brain natriuretic peptide in the plasma predicts outcomes of treatment of children with decompensated heart failure admitted to the intensive care unit. Cardiol Young 17:397–406CrossRefPubMed
14.
Zurück zum Zitat Puddy VF, Amirmansour C, Williams AF, Singer DR (2002) Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci Lond 103:75–77CrossRefPubMed Puddy VF, Amirmansour C, Williams AF, Singer DR (2002) Plasma brain natriuretic peptide as a predictor of haemodynamically significant patent ductus arteriosus in preterm infants. Clin Sci Lond 103:75–77CrossRefPubMed
15.
Zurück zum Zitat Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J (2002) Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110:e76CrossRefPubMed Mir TS, Marohn S, Laer S, Eiselt M, Grollmus O, Weil J (2002) Plasma concentrations of N-terminal pro-brain natriuretic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure. Pediatrics 110:e76CrossRefPubMed
16.
Zurück zum Zitat Kunii Y, Kamada M, Ohtsuki S, Araki T, Kataoka K, Kageyama M, Nakagawa N, Seino Y (2003) Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 57:191–197PubMed Kunii Y, Kamada M, Ohtsuki S, Araki T, Kataoka K, Kageyama M, Nakagawa N, Seino Y (2003) Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 57:191–197PubMed
17.
Zurück zum Zitat Shaddy RE (2001) Optimizing treatment for chronic congestive heart failure in children. Crit Care Med 29:S237–S240CrossRefPubMed Shaddy RE (2001) Optimizing treatment for chronic congestive heart failure in children. Crit Care Med 29:S237–S240CrossRefPubMed
18.
Zurück zum Zitat Bautista-Hernandez V, Sanchez-Andres A, Portela F, Fynn-Thompson F (2011) Current pharmacologic management of pediatric heart failure in congenital heart disease. Curr Vasc Pharmacol 9:619–628CrossRefPubMed Bautista-Hernandez V, Sanchez-Andres A, Portela F, Fynn-Thompson F (2011) Current pharmacologic management of pediatric heart failure in congenital heart disease. Curr Vasc Pharmacol 9:619–628CrossRefPubMed
19.
Zurück zum Zitat Berman W Jr, Yabek SM, Dillon T, Niland C, Corlew S, Christensen D (1983) Effects of digoxin in infants with congested circulatory state due to a ventricular septal defect. N Engl J Med 308:363–366CrossRefPubMed Berman W Jr, Yabek SM, Dillon T, Niland C, Corlew S, Christensen D (1983) Effects of digoxin in infants with congested circulatory state due to a ventricular septal defect. N Engl J Med 308:363–366CrossRefPubMed
20.
Zurück zum Zitat Kimball TR, Daniels SR, Meyer RA, Hannon DW, Tian J, Shukla R, Schwartz DC (1991) Effect of digoxin on contractility and symptoms in infants with a large ventricular septal defect. Am J Cardiol 68:1377–1382CrossRefPubMed Kimball TR, Daniels SR, Meyer RA, Hannon DW, Tian J, Shukla R, Schwartz DC (1991) Effect of digoxin on contractility and symptoms in infants with a large ventricular septal defect. Am J Cardiol 68:1377–1382CrossRefPubMed
21.
Zurück zum Zitat Kothari SS (1997) Does digoxin still have a role in congestive heart failure? Indian J Pediatr 64:833–837CrossRefPubMed Kothari SS (1997) Does digoxin still have a role in congestive heart failure? Indian J Pediatr 64:833–837CrossRefPubMed
22.
Zurück zum Zitat Redington AN, Carvalho JS, Shinebourne EA (1989) Does digoxin have a place in the treatment of the child with congenital heart disease? Cardiovasc Drugs Ther 3:21–24CrossRefPubMed Redington AN, Carvalho JS, Shinebourne EA (1989) Does digoxin have a place in the treatment of the child with congenital heart disease? Cardiovasc Drugs Ther 3:21–24CrossRefPubMed
23.
Zurück zum Zitat Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ (2004) N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence: elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 93:603–607CrossRefPubMed Nir A, Bar-Oz B, Perles Z, Brooks R, Korach A, Rein AJ (2004) N-terminal pro-B-type natriuretic peptide: reference plasma levels from birth to adolescence: elevated levels at birth and in infants and children with heart diseases. Acta Paediatr 93:603–607CrossRefPubMed
25.
Zurück zum Zitat Ross RD, Bollinger RO, Pinsky WW (1992) Grading the severity of congestive heart failure in infants. Pediatr Cardiol 13:72–75CrossRefPubMed Ross RD, Bollinger RO, Pinsky WW (1992) Grading the severity of congestive heart failure in infants. Pediatr Cardiol 13:72–75CrossRefPubMed
26.
Zurück zum Zitat Reithmann C, Reber D, Kozlik-Feldmann R, Netz H, Pilz G, Welz A, Werdan K (1997) A post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease. Eur J Pharmacol 330:79–86CrossRefPubMed Reithmann C, Reber D, Kozlik-Feldmann R, Netz H, Pilz G, Welz A, Werdan K (1997) A post-receptor defect of adenylyl cyclase in severely failing myocardium from children with congenital heart disease. Eur J Pharmacol 330:79–86CrossRefPubMed
27.
Zurück zum Zitat Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358–367CrossRefPubMed Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, Gutgesell H, Reichek N, Sahn D, Schnittger I et al (1989) Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2:358–367CrossRefPubMed
28.
Zurück zum Zitat Jain S, Vaidyanathan B (2009) Digoxin in management of heart failure in children: should it be continued or relegated to the history books? Ann Pediatr Cardiol 2:149–152PubMedCentralCrossRefPubMed Jain S, Vaidyanathan B (2009) Digoxin in management of heart failure in children: should it be continued or relegated to the history books? Ann Pediatr Cardiol 2:149–152PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Yoshibayashi M, Kamiya T, Saito Y, Nakao K, Nishioka K, Temma S, Itoh H, Shirakami G, Matsuo H (1995) Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 133:207–209CrossRefPubMed Yoshibayashi M, Kamiya T, Saito Y, Nakao K, Nishioka K, Temma S, Itoh H, Shirakami G, Matsuo H (1995) Plasma brain natriuretic peptide concentrations in healthy children from birth to adolescence: marked and rapid increase after birth. Eur J Endocrinol 133:207–209CrossRefPubMed
30.
Zurück zum Zitat Mir TS, Flato M, Falkenberg J, Haddad M, Budden R, Weil J, Albers S, Laer S (2006) Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender. Pediatr Cardiol 27:73–77CrossRefPubMed Mir TS, Flato M, Falkenberg J, Haddad M, Budden R, Weil J, Albers S, Laer S (2006) Plasma concentrations of N-terminal brain natriuretic peptide in healthy children, adolescents, and young adults: effect of age and gender. Pediatr Cardiol 27:73–77CrossRefPubMed
31.
Zurück zum Zitat Cardoso J, Brito MI, Ochiai ME, Novaes M, Berganin F, Thicon T, Ferreira EC, Regina K, Reis CM, Barretto AC (2010) Anemia in patients with advanced heart failure. Arq Bras Cardiol 95:524–528CrossRefPubMed Cardoso J, Brito MI, Ochiai ME, Novaes M, Berganin F, Thicon T, Ferreira EC, Regina K, Reis CM, Barretto AC (2010) Anemia in patients with advanced heart failure. Arq Bras Cardiol 95:524–528CrossRefPubMed
32.
Zurück zum Zitat Ralli S, Horwich TB, Fonarow GC (2005) Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 150:1220–1227CrossRefPubMed Ralli S, Horwich TB, Fonarow GC (2005) Relationship between anemia, cardiac troponin I, and B-type natriuretic peptide levels and mortality in patients with advanced heart failure. Am Heart J 150:1220–1227CrossRefPubMed
33.
Zurück zum Zitat Wu YR, Chen SB, Huang MR, Zhang YQ, Sun K, Chen S (2005) Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects. Zhonghua Er Ke Za Zhi 43:161–164PubMed Wu YR, Chen SB, Huang MR, Zhang YQ, Sun K, Chen S (2005) Diagnostic value of plasma concentration of pro-brain natriuretic peptide in congestive heart failure in pediatric patients with ventricular septal defects. Zhonghua Er Ke Za Zhi 43:161–164PubMed
34.
Zurück zum Zitat Zhang SR, Zhang YH, Xu Q, Qiu HX, Chen Q (2009) Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease. Zhongguo Dang Dai Er Ke Za Zhi 11:429–432PubMed Zhang SR, Zhang YH, Xu Q, Qiu HX, Chen Q (2009) Values of brain natriuretic peptide and N-terminal pro-brain natriuretic peptide in evaluation of cardiac function in children with congenital heart disease. Zhongguo Dang Dai Er Ke Za Zhi 11:429–432PubMed
Metadaten
Titel
Evaluation by N-terminal Prohormone of Brain Natriuretic Peptide Concentrations and Ross Scoring of the Efficacy of Digoxin in the Treatment of Heart Failure Secondary to Congenital Heart Disease With Left-to-Right Shunts
verfasst von
Ozlem Elkiran
Ayse Sandikkaya
Gulendam Kocak
Cemsit Karakurt
Cagatay Taskapan
Saim Yologlu
Publikationsdatum
01.10.2013
Verlag
Springer US
Erschienen in
Pediatric Cardiology / Ausgabe 7/2013
Print ISSN: 0172-0643
Elektronische ISSN: 1432-1971
DOI
https://doi.org/10.1007/s00246-013-0683-7

Weitere Artikel der Ausgabe 7/2013

Pediatric Cardiology 7/2013 Zur Ausgabe

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.